We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0I8C market cap is 130.25M. The company's latest EPS is NOK -0.9063 and P/E is -6.95.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 1.22M | 1.3M | 812k | 1.98M | 7.16M |
| Operating Income | -18.37M | -13.12M | -16.04M | -17.8M | -16.3M |
| Net Income | -18.36M | -13.22M | -14.7M | -19.11M | -18.74M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 30.04M | 10.39M | 16.24M | 34.43M | 67.2M |
| Total Liabilities | 10.13M | 3.06M | 7.92M | 15.72M | 65.34M |
| Total Equity | 19.91M | 7.32M | 8.32M | 18.71M | 1.86M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | -17.31M | -17.19M | -13.34M | -20.97M | -15.45M |
| Investing | -358k | -18k | -3.27M | -5.41M | -4.09M |
| Financing | -898k | 20.71M | 15.16M | 34.3M | 8.05M |
| Market Cap | 130.25M |
| Price to Earnings Ratio | -6.95 |
| Price to Sales Ratio | 18.19 |
| Price to Cash Ratio | 88.11 |
| Price to Book Ratio | 69.99 |
| Dividend Yield | - |
| Shares Outstanding | 20.67M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 6.30 |
| 52 Week Low | 6.30 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aqua Bio Technology Asa |
| Address |
torm��hlens gate 55 bergen |
| Website | https://www.aquabiotechnology.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
